• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

RSNA: Nonin Medical Launches First FDA-Cleared OTC Fingertip Pulse Oximeter for Accurate Readings Across Skin Tones

by Fred Pennic 12/02/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Nonin Medical, a global leader in noninvasive medical monitoring lauches TruO2 OTC, the first over-the-counter (OTC) fingertip pulse oximeter to receive FDA clearance. This innovative device is designed to provide accurate blood oxygen saturation readings for adults across all skin tones, empowering individuals to make informed healthcare decisions.

– Nonin Medical’s founder, Phil Isaacson, was the original inventor of the fingertip pulse oximeter.  The TruO2 OTC continues this legacy of innovation, providing consumers with access to accurate and reliable medical-grade technology.

Addressing Inaccuracies in Consumer Pulse Oximeters

Many pulse oximeters available to consumers are classified as “health and wellness devices,” meaning they are not subject to the stringent accuracy requirements of FDA-cleared medical devices. This has led to concerns about the reliability of these devices, particularly for individuals with darker skin tones.

Studies have shown that some low-cost pulse oximeters can produce inaccurate readings, potentially leading to missed diagnoses and delayed treatment. This issue is particularly concerning for patients with darker skin, as research indicates they are more likely to have their blood oxygen levels overestimated by these devices.

“Over the past several years, the US market has been flooded with poor quality, health and wellness grade pulse oximeters which are not regulated by the FDA. This creates a confusing and frustrating experience for consumers, including those with conditions like COPD or asthma, seeking an accurate, equitable, and durable solution for home use,” John Hastings, CEO of Nonin Medical, explains.

Nonin’s Commitment to Accuracy

Nonin Medical has a long-standing commitment to developing highly accurate pulse oximetry devices that perform reliably across all skin tones. The TruO2 OTC builds on this legacy, offering:

  • FDA Clearance: Ensures the device meets the FDA’s rigorous standards for medical devices, guaranteeing accuracy and reliability.
  • Proven Accuracy: Multiple independent studies have demonstrated the accuracy of Nonin’s pulse oximetry technology across diverse skin tones.
  • Accessibility: Available over-the-counter, making it convenient for consumers to purchase.

Availability

The TruO2 OTC fingertip pulse oximeter will be available for purchase on Amazon in December 2024 and from other online retailers soon after.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: FDA Clearance

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |